GlaxoSmithKline posts results of Phase 3 B-Well 2 study of bepirovirsen in chronic hepatitis B
The study enrolled 857 participants and completed primary data collection on November 3, 2025. Results were first posted on ClinicalTrials.gov on November 20, 2026.
Primary source
ClinicalTrials.gov results record, November 20, 2026
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
Read the source: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation